

Docket No. JBP-462

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Charles E. Clum et al.

JAN 2 1 2000

Serial No.

09/360,805

Art Unit: 1614

Filed

July 23, 1999

Examiner:

For

RETINOID COMPOSITIONS CONTAINING WATER SOLUBLE

ANTIOXIDANT AND A CHELATOR

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner For Patents, Washington, D.C. 20231 on

January 14, 2000

(Date of Deposit)

William E. McGowan

(Name of applicant assigner or Registered Representative

January 14, 2000

(Date of Signature)

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in

§1.491, or before the mailing date of a first Office Action on the merits of the above-identified
application, no additional fee is required.
☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:
Certification in Accordance with §1.97(e) is set forth below; or
Please charge Deposit Account No. 10-0750/ / the fee of \$240.00 as set forth in §1.17(p).
In accordance with §1.97(c), this Information Disclosure Statement is being filed
after the period set forth in §1.97(b) above but before the mailing date of either a Final Action
under §1.113 or a Notice of Allowance under §1.311, therefore:
Certification in Accordance with §1.97(e) is set forth below; or
Please charge Deposit Account No. 10-0750/ / the fee of \$240.00
as set forth in §1.17(p).
In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Certification in Accordance with §1.97(e) as set forth below and the fee of \$130.00 as set forth in §1.17(i)(1).
form below and the fee of <u>\$150.00</u> as set form in \$1.17(1)(1).
Copies of each of the references listed on the attached Form PTO-1449 are
enclosed herewith.
Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. §120 have been made in the instant application: Copies of references [list as appropriate] listed on the attached Form PTO- \boxtimes 1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 08/674,474, filed July 2, 1996: US 3,906,108 US 4,214,000 US 4,247,547 US 4,466,805 US 4,603,146 US 4,720,353 US 4,826,828 US 4,877,805 Japanese Patent No. 53-14607 Japanese Patent No. 58-41813 References: Dittert, L.W., Sprowl's American Pharmacy, 7th Ed., p. 471

Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 07/719,264, filed June 27, 1991:

McCutcheon's Emulsifier's and Detergents, Vo.l. 1, p. 250

Remington's Pharmaceutical Science, 15th Ed., pp. 329-337 (1975) Sprowls, J.B. Jr., Prescription Pharmacy, 2nd Ed., pp. 220-223 (1970)

If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

(1974)

(1991)

The relevance of those listed references which are not in the English language is as follows: references cited: AT-B-364 711, as recited in claim 1, Austrian Patent No. 364,711 claims cosmetic compositions for bronzing the skin and dying the hair containing a high content of a Formula I. EP 343 444 - Derwent abstract attached DE 3514724 - Derwent abstract attached FR 3400M - translation is provided JP 58-41813 - translation provided in USSN 08/674,474 JP 53-14607 - translation provided in USSN 08/674,474 There are no listed references which are not in the English language. П Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JBP-462/WEM. This form is submitted in triplicate.

Respectfully submitted,

William E. McGowan

Reg. No. 39,301

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2197 DATED: January 14, 2000